Ogivri

Random entry RSS

Posted in:
Legal

Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents
By Benjamin R. Holt December 5, 2017 Comments are off
The FDA has only approved eight biosimilar products to date. The second most recently approved biosimilar is Mvasi (bevacizumab-awwb),...

Read more

Tagged with: Amgen, Avastin®, bevacizumab, Biocon, BPCIA, FDA, Genentech, Herceptin®, Mvasi, Mylan, Ogivri

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top